DE69730966T2 - Morphogenische behandlung des chronischen nierenversagens - Google Patents
Morphogenische behandlung des chronischen nierenversagens Download PDFInfo
- Publication number
- DE69730966T2 DE69730966T2 DE69730966T DE69730966T DE69730966T2 DE 69730966 T2 DE69730966 T2 DE 69730966T2 DE 69730966 T DE69730966 T DE 69730966T DE 69730966 T DE69730966 T DE 69730966T DE 69730966 T2 DE69730966 T2 DE 69730966T2
- Authority
- DE
- Germany
- Prior art keywords
- mammal
- renal
- gfr
- chronic
- bmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 107
- 208000022831 chronic renal failure syndrome Diseases 0.000 title claims abstract description 100
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 230000000921 morphogenic effect Effects 0.000 title description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 80
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims abstract description 18
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims abstract description 18
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 230000002188 osteogenic effect Effects 0.000 claims abstract description 9
- 235000018102 proteins Nutrition 0.000 claims description 77
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 68
- 241000124008 Mammalia Species 0.000 claims description 59
- 210000003734 kidney Anatomy 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 48
- 210000000885 nephron Anatomy 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 230000003907 kidney function Effects 0.000 claims description 37
- 230000001684 chronic effect Effects 0.000 claims description 35
- 229940109239 creatinine Drugs 0.000 claims description 34
- 210000004899 c-terminal region Anatomy 0.000 claims description 30
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 25
- 102000046107 human BMP7 Human genes 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 25
- 230000037396 body weight Effects 0.000 claims description 23
- 239000013543 active substance Substances 0.000 claims description 22
- 239000000556 agonist Substances 0.000 claims description 22
- 230000004069 differentiation Effects 0.000 claims description 21
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 206010020880 Hypertrophy Diseases 0.000 claims description 15
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 14
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 14
- -1 OP-3 Proteins 0.000 claims description 14
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 13
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 11
- 238000000502 dialysis Methods 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 230000024924 glomerular filtration Effects 0.000 claims description 10
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 9
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 9
- 230000001434 glomerular Effects 0.000 claims description 9
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 230000001631 hypertensive effect Effects 0.000 claims description 8
- 239000000411 inducer Substances 0.000 claims description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
- 208000034189 Sclerosis Diseases 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 7
- 201000009925 nephrosclerosis Diseases 0.000 claims description 7
- 230000002485 urinary effect Effects 0.000 claims description 7
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 6
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 6
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 claims description 6
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 6
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 claims description 6
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 6
- 206010038468 Renal hypertrophy Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 201000008627 kidney hypertrophy Diseases 0.000 claims description 6
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 6
- 201000002793 renal fibrosis Diseases 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 4
- 201000000523 end stage renal failure Diseases 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010038433 renal dysplasia Diseases 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 208000022461 Glomerular disease Diseases 0.000 claims description 3
- 230000022159 cartilage development Effects 0.000 claims description 3
- 238000002591 computed tomography Methods 0.000 claims description 3
- 208000028208 end stage renal disease Diseases 0.000 claims description 3
- 238000011862 kidney biopsy Methods 0.000 claims description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- 238000011835 investigation Methods 0.000 claims 2
- 101710167839 Morphogenetic protein Proteins 0.000 claims 1
- 150000007854 aminals Chemical class 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 35
- 238000012959 renal replacement therapy Methods 0.000 abstract description 21
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 11
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 8
- 241000700159 Rattus Species 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 31
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 210000005084 renal tissue Anatomy 0.000 description 24
- 210000002700 urine Anatomy 0.000 description 24
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 22
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 22
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 22
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 22
- 230000000750 progressive effect Effects 0.000 description 20
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 19
- 101000899367 Mus musculus Bone morphogenetic protein 8A Proteins 0.000 description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 201000006370 kidney failure Diseases 0.000 description 16
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 15
- 208000001647 Renal Insufficiency Diseases 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 208000009304 Acute Kidney Injury Diseases 0.000 description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
- 208000033626 Renal failure acute Diseases 0.000 description 11
- 201000011040 acute kidney failure Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 210000005239 tubule Anatomy 0.000 description 10
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 9
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000012998 acute renal failure Diseases 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 8
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000001002 morphogenetic effect Effects 0.000 description 8
- 238000013059 nephrectomy Methods 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 101100339496 Caenorhabditis elegans hop-1 gene Proteins 0.000 description 6
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 6
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 5
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 5
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000009256 replacement therapy Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 4
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 150000001945 cysteines Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 3
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 description 3
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 3
- 101710204283 Growth/differentiation factor 7 Proteins 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 208000000223 Solitary Kidney Diseases 0.000 description 3
- 239000002269 analeptic agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 238000011961 computed axial tomography Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 241001156002 Anthonomus pomorum Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000035126 Facies Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 2
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 2
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 2
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 2
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 2
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 208000009857 Microaneurysm Diseases 0.000 description 2
- 101000899362 Mus musculus Bone morphogenetic protein 7 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000035194 endochondral ossification Effects 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 229940011059 p-aminohippurate Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000007425 progressive decline Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- KLXQAXYSOJNJRI-KVTDHHQDSA-N (2s,3s,4r,5r)-5-amino-2,3,4,6-tetrahydroxyhexanal Chemical compound OC[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)C=O KLXQAXYSOJNJRI-KVTDHHQDSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 description 1
- 102100028727 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016726 Coat Protein Complex I Human genes 0.000 description 1
- 108010092897 Coat Protein Complex I Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108700005865 Drosophila gbb Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010051283 Fluid imbalance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 1
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 101000766116 Haloarcula vallismortis Cruxrhodopsin-3 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 description 1
- 101000899364 Homo sapiens Bone morphogenetic protein 8A Proteins 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101000848718 Homo sapiens Rap guanine nucleotide exchange factor 5 Proteins 0.000 description 1
- 101000651373 Homo sapiens Serine palmitoyltransferase small subunit B Proteins 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100027676 Serine palmitoyltransferase small subunit B Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 108010027904 cartilage-derived-morphogenetic protein-2 Proteins 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002670 chondrogenetic effect Effects 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000010133 endochondral bone morphogenesis Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000043629 human RAPGEF5 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010071304 univin Proteins 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US643321 | 1996-05-06 | ||
| US08/643,321 US6498142B1 (en) | 1996-05-06 | 1996-05-06 | Morphogen treatment for chronic renal failure |
| PCT/US1997/007816 WO1997041881A1 (en) | 1996-05-06 | 1997-05-06 | Morphogen treatment for chronic renal failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69730966D1 DE69730966D1 (de) | 2004-11-04 |
| DE69730966T2 true DE69730966T2 (de) | 2006-02-23 |
Family
ID=24580305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69723845T Expired - Lifetime DE69723845T2 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
| DE69730966T Expired - Lifetime DE69730966T2 (de) | 1996-05-06 | 1997-05-06 | Morphogenische behandlung des chronischen nierenversagens |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69723845T Expired - Lifetime DE69723845T2 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US6498142B1 (enExample) |
| EP (2) | EP0914146B1 (enExample) |
| JP (4) | JP2000510835A (enExample) |
| AT (2) | ATE277629T1 (enExample) |
| AU (2) | AU2933997A (enExample) |
| CA (2) | CA2254954C (enExample) |
| DE (2) | DE69723845T2 (enExample) |
| DK (2) | DK0910400T3 (enExample) |
| ES (2) | ES2203803T3 (enExample) |
| PT (2) | PT910400E (enExample) |
| WO (2) | WO1997041881A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2363965C (en) * | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| PT980252E (pt) | 1997-05-05 | 2005-01-31 | Curis Inc | Terapias para insuficiencia renal aguda |
| AU7473098A (en) * | 1997-05-07 | 1998-11-27 | Biogen, Inc. | Novel therapies for cystic kidney disease |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| US6203788B1 (en) * | 1997-09-29 | 2001-03-20 | Adherex Inc. | Compounds and methods for regulating cell adhesion |
| EP1037910A2 (en) * | 1997-12-04 | 2000-09-27 | Curis, Inc. | Maintenance of smooth muscle integrity by morphogenic proteins |
| WO2000006716A1 (en) * | 1998-07-28 | 2000-02-10 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
| US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
| AU783266B2 (en) * | 1999-09-14 | 2005-10-06 | Biogen Ma Inc. | Therapies for chronic renal failure using one or more integrin antagonists |
| US20020173453A1 (en) * | 2000-12-15 | 2002-11-21 | Rama Akella | Method of treating renal injury |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7232802B2 (en) * | 2001-12-21 | 2007-06-19 | Zimmer Orthobiologics, Inc. | Compositions and methods for promoting myocardial and peripheral angiogenesis |
| US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| JP2006516020A (ja) * | 2002-08-28 | 2006-06-15 | キュリス インコーポレイテッド | 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与 |
| EP2441474B1 (en) | 2003-10-17 | 2015-08-05 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| US7844367B2 (en) | 2003-12-23 | 2010-11-30 | Rain Bird Corporation | Code replacement for irrigation controllers |
| CA2557848C (en) * | 2004-03-30 | 2013-12-10 | Ilypsa, Inc. | Ion binding compositions |
| CA2561809A1 (en) * | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| US20100150885A1 (en) * | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| US7771995B2 (en) * | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP3147296A1 (en) | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| WO2007087570A2 (en) | 2006-01-24 | 2007-08-02 | Northfield Laboratories, Inc. | Polymerized hemoglobin media and its use in isolation and transplantation of islet cells |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| ATE539351T1 (de) | 2006-05-30 | 2012-01-15 | Antibodyshop As | Verfahren zur schnellen beurteilung der schwere eines traumas |
| US7722665B2 (en) * | 2006-07-07 | 2010-05-25 | Graft Technologies, Inc. | System and method for providing a graft in a vascular environment |
| WO2008010556A1 (fr) * | 2006-07-21 | 2008-01-24 | Chugai Seiyaku Kabushiki Kaisha | Médicament agissant contre une maladie rénale |
| EP2114390A2 (en) * | 2006-12-15 | 2009-11-11 | Ruprecht-Karls-Universität Heidelberg | Methods for treating podocyte-related disorders |
| AU2008245900B2 (en) * | 2007-04-24 | 2013-07-25 | Advanced Technologies And Regenerative Medicine, Llc | Engineered renal tissue |
| DE102007034580B4 (de) * | 2007-07-13 | 2012-11-08 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Biomaterial basierend auf einem hydrophilen polymeren Träger |
| US20090155245A1 (en) * | 2007-12-18 | 2009-06-18 | Fang Carrie H | Treatment for Organ Regeneration with Combination of Drug and Biologics |
| AU2009244308A1 (en) * | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| WO2009157165A1 (ja) * | 2008-06-24 | 2009-12-30 | 株式会社根本杏林堂 | 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法 |
| EP2324355B1 (en) * | 2008-08-28 | 2014-01-22 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2813848A3 (en) * | 2008-08-29 | 2015-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP2012506538A (ja) * | 2008-10-21 | 2012-03-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
| CA2740788C (en) | 2008-10-21 | 2023-03-14 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN104330574B (zh) | 2008-11-10 | 2017-04-12 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| EP2364370B1 (en) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2393937A4 (en) * | 2009-02-06 | 2012-08-08 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| SG2014010680A (en) * | 2009-02-12 | 2014-04-28 | Stryker Corp | Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease |
| US20100204124A1 (en) * | 2009-02-12 | 2010-08-12 | Mary Elizabeth Pecquet Goad | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members |
| CN102369212B (zh) | 2009-03-12 | 2015-12-16 | 哈瑟投资公司 | 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体 |
| US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| BR112012002711A2 (pt) | 2009-08-07 | 2016-11-01 | Astute Medical Inc | metodo para avaliar o estado renal em um individuo, e, medicao de proteina |
| JP2013518808A (ja) | 2009-09-17 | 2013-05-23 | ストライカー コーポレイション | 骨形成タンパク質のｐＨを制御するための緩衝液 |
| CN102725635B (zh) | 2009-11-07 | 2015-05-20 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| ES2818138T3 (es) | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| AU2010341565A1 (en) | 2009-12-22 | 2012-07-12 | Stryker Corporation | BMP-7 variants with reduced immunogenicity |
| RS54879B1 (sr) | 2010-02-05 | 2016-10-31 | Astute Medical Inc | Metode i kompozicije za dijagnoze i prognoze oštećenja bubrega i bubrežne insuficijencije |
| WO2011162819A1 (en) | 2010-06-23 | 2011-12-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011220413B2 (en) | 2010-02-26 | 2015-07-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ｎｇａｌタンパク質変異体及びその使用 |
| EP2585827A4 (en) | 2010-06-23 | 2013-12-04 | Astute Medical Inc | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency |
| KR101630501B1 (ko) | 2010-08-20 | 2016-06-15 | 와이어쓰 엘엘씨 | 디자이너 골형성 단백질 |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| EP2788759B1 (en) | 2011-12-08 | 2019-02-20 | Astute Medical, Inc. | Methods and uses for diagnosis of renal injury and renal failure |
| CA2886788C (en) | 2012-10-08 | 2022-04-19 | Relypsa, Inc. | Potassium-binding agents for treating hypertension and hyperkalemia |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| EP4105657B1 (en) | 2013-01-17 | 2024-09-25 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
| EP3069149B1 (en) * | 2013-11-11 | 2022-05-18 | General Electric Company | Method for reducing error in rotor speed measurements |
| EP2944326B1 (en) | 2014-05-16 | 2018-11-21 | Cyanagen Srl | Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases |
| CA2976376A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| US11243217B2 (en) | 2016-06-06 | 2022-02-08 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| AU2017312113B2 (en) | 2016-08-17 | 2023-05-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| JP2019039673A (ja) * | 2017-08-22 | 2019-03-14 | セイコーエプソン株式会社 | 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5011691A (en) * | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5045452A (en) * | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| ES2113857T3 (es) | 1989-03-28 | 1998-05-16 | Genetics Inst | Composiciones osteoinductoras. |
| DK0536186T3 (da) | 1990-05-16 | 2002-05-21 | Genetics Inst | Knogle- og brusk-dannelsesfremkaldende proteiner |
| JPH0426624A (ja) * | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| DK0533840T3 (da) | 1990-06-22 | 1996-12-30 | Du Pont | Behandling af kronisk nyresvigt med imidazol-angiotensin-II-receptor-antagonister |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US7056882B2 (en) | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6194376B1 (en) | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| CA2363965C (en) | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| EP0575555B1 (en) | 1991-03-11 | 2001-07-18 | Curis, Inc. | Protein-induced morphogenesis |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| EP0601135B1 (en) | 1991-08-30 | 2005-11-02 | Curis, Inc. | Osteogenic proteins in the treatment of metabolic bone diseases |
| WO1993005172A1 (en) | 1991-08-30 | 1993-03-18 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
| WO1993004692A1 (en) | 1991-08-30 | 1993-03-18 | Creative Biomolecules, Inc. | Morphogen-induced modulation of inflammatory response |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| DE69333040T3 (de) | 1992-07-31 | 2007-10-11 | Curis, Inc., Cambridge | Morphogen induzierte nerven wiederherstellung und wiedergutmachung. |
| DE69318166T2 (de) | 1992-07-31 | 1998-10-08 | Creative Biomolecules, Inc., Hopkinton, Mass. | Mit morphogen angereicherte nahrungszusammenstellung |
| ATE287949T1 (de) | 1992-07-31 | 2005-02-15 | Stryker Corp | Löslicher komplex morphogener proteine und zusammensetzungen davon |
| ES2114073T3 (es) | 1992-09-16 | 1998-05-16 | Creative Biomolecules Inc | Regeneracion del higado inducida por morfogenes. |
| AU681362B2 (en) | 1992-11-03 | 1997-08-28 | Stryker Corporation | OP-3-induced morphogenesis |
| US5372335A (en) | 1992-12-18 | 1994-12-13 | Scott H. Yenzer | Aerial marker ball and method of placement |
| JPH08510446A (ja) | 1993-03-04 | 1996-11-05 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 組換え骨形成タンパク質を生成するための方法および組成物 |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| ATE225666T1 (de) * | 1993-11-15 | 2002-10-15 | Celtrix Pharma | Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US5723411A (en) * | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
| US6407060B1 (en) | 1996-03-22 | 2002-06-18 | Curis, Inc. | Method for enhancing functional recovery following central nervous system ischemia or trauma |
| US5820589A (en) | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) * | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1996
- 1996-05-06 US US08/643,321 patent/US6498142B1/en not_active Expired - Lifetime
-
1997
- 1997-05-06 WO PCT/US1997/007816 patent/WO1997041881A1/en not_active Ceased
- 1997-05-06 AT AT97922726T patent/ATE277629T1/de active
- 1997-05-06 EP EP97922726A patent/EP0914146B1/en not_active Expired - Lifetime
- 1997-05-06 PT PT97923567T patent/PT910400E/pt unknown
- 1997-05-06 DK DK97923567T patent/DK0910400T3/da active
- 1997-05-06 DE DE69723845T patent/DE69723845T2/de not_active Expired - Lifetime
- 1997-05-06 WO PCT/US1997/007655 patent/WO1997041880A1/en not_active Ceased
- 1997-05-06 ES ES97923567T patent/ES2203803T3/es not_active Expired - Lifetime
- 1997-05-06 JP JP09540150A patent/JP2000510835A/ja active Pending
- 1997-05-06 AU AU29339/97A patent/AU2933997A/en not_active Abandoned
- 1997-05-06 AU AU28322/97A patent/AU2832297A/en not_active Abandoned
- 1997-05-06 AT AT97923567T patent/ATE245997T1/de not_active IP Right Cessation
- 1997-05-06 CA CA002254954A patent/CA2254954C/en not_active Expired - Fee Related
- 1997-05-06 DK DK97922726T patent/DK0914146T3/da active
- 1997-05-06 CA CA002254953A patent/CA2254953C/en not_active Expired - Fee Related
- 1997-05-06 EP EP97923567A patent/EP0910400B1/en not_active Expired - Lifetime
- 1997-05-06 ES ES97922726T patent/ES2230604T3/es not_active Expired - Lifetime
- 1997-05-06 PT PT97922726T patent/PT914146E/pt unknown
- 1997-05-06 DE DE69730966T patent/DE69730966T2/de not_active Expired - Lifetime
- 1997-05-06 JP JP54021197A patent/JP4766722B2/ja not_active Expired - Fee Related
- 1997-05-06 US US08/851,628 patent/US6861404B1/en not_active Expired - Fee Related
-
2004
- 2004-12-17 US US11/016,499 patent/US7524817B2/en not_active Expired - Fee Related
-
2009
- 2009-03-16 US US12/404,559 patent/US8017580B2/en not_active Expired - Fee Related
- 2009-05-26 JP JP2009126963A patent/JP5247593B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-11 US US13/207,584 patent/US8377878B2/en not_active Expired - Fee Related
-
2012
- 2012-08-14 JP JP2012179876A patent/JP2012229268A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69730966T2 (de) | Morphogenische behandlung des chronischen nierenversagens | |
| DE69723429T2 (de) | Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns | |
| DE69814352T3 (de) | Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung | |
| DE69431527T2 (de) | Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung | |
| DE69233559T2 (de) | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten | |
| DE69634301T2 (de) | Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf) | |
| DE69231062T2 (de) | Morphogen-induzierte Modulation von entzündlichen Antworten | |
| DE69913665T2 (de) | Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten | |
| DE69333040T3 (de) | Morphogen induzierte nerven wiederherstellung und wiedergutmachung. | |
| DE69915310T2 (de) | Methoden zur behandlung der salzabhängigen hypertonie | |
| EP2099472B1 (en) | Intra-vascular kidney gene therapy with plasmid encoding bmp-7 | |
| DE69826854T2 (de) | Therapien zur behandlung von akutem nierenversagen | |
| DE69920033T2 (de) | Verfahren zur verminderung von krebssymptomen | |
| DE69832880T2 (de) | Frazzled nukleotidsequenzen, expressionsprodukte, zusammensetzungen und verwendungen | |
| DE69720275T2 (de) | Die von morphogenen peptiden hervorgerufene wiederherstellung von gewebe aus sinneszellen | |
| AU767112B2 (en) | Morphogen treatment for chronic renal failure | |
| AU757969B2 (en) | Therapies for chronic renal failure | |
| US20240342342A1 (en) | Nerve grafts for peripheral nerve regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: STRYKER CORP., KALAMAZOO, MICH., US |